John M. Lambert
-
- Monoclonal and Polyclonal Antibodies Research 52
- Oncology top 0.5%
- HER2/EGFR in Cancer Research 32
- CAR-T cell therapy research 14
- Biotechnology top 0.5%
- Transgenic Plants and Applications 24
- Immunology top 1%
- Toxin Mechanisms and Immunotoxins 39
- Molecular Biology top 2%
- RNA and protein synthesis mechanisms 12
- Glycosylation and Glycoproteins Research 10
-
- Lymphoma Diagnosis and Treatment 9
- Co-authors
- Ravi ChariWalter A. BlättlerVictor S. GoldmacherRobert R. TrautPeter D. SenterRobert J. LutzAnna BerkenblitCharles Morris
- Partner nations
- United StatesUnited KingdomFrance
In The Last Decade
John M. Lambert
128 papers receiving 7.8k citations
Hit Papers
Peers
Comparison fields: 5 of 144
- Radiology, Nuclear Medicine and Imaging 3.9k
- Oncology 4.0k
- Biotechnology 797
- Immunology 1.8k
- Molecular Biology 3.4k
Countries citing papers authored by John M. Lambert
This map shows the geographic impact of John M. Lambert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John M. Lambert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John M. Lambert more than expected).
Fields of papers citing papers by John M. Lambert
This network shows the impact of papers produced by John M. Lambert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John M. Lambert. The network helps show where John M. Lambert may publish in the future.
Co-authorship network
The 25 scholars most cited alongside John M. Lambert, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Antibody–drug conjugates come of age in oncologybreakdown → | 2023 | 460 |
| 2 | 2017 | 2 | |
| 3 | 2016 | 65 | |
| 4 | 2015 | 160 | |
| 5 | 2013 | 79 | |
| 6 | 2013 | 57 | |
| 7 | 2012 | 31 | |
| 8 | Preclinical evaluation of huC242-DM4 in tumor xenograft models of canag-positive human gastric cancer | 2007 | 1 |
| 9 | Novel anti-CD33 immunoconjugate demonstrating in vitro and in vivo activity against human acute myeloid leukemia (AML) cells. | 2006 | 1 |
| 10 | HuC242-DM4, an antibody-maytansinoid conjugate with superior preclinical activity in human CanAg-positive tumor xenograft models in SCID mice | 2005 | 5 |
| 11 | 2005 | 20 | |
| 12 | 2004 | 103 | |
| 13 | 2002 | 19 | |
| 14 | 2002 | 258 | |
| 15 | 1997 | 71 | |
| 16 | 1996 | 40 | |
| 17 | 1996 | 26 | |
| 18 | 1994 | 15 | |
| 19 | 1994 | 10 | |
| 20 | Effects of anti-CD33 blocked ricin immunotoxin on the capacity of CD34+ human marrow cells to establish in vitro hematopoiesis in long-term marrow cultures. | 1992 | 20 |
About John M. Lambert
John M. Lambert is a scholar working on Biotechnology, Radiology, Nuclear Medicine and Imaging, Immunology, Oncology and Space and Planetary Science, having authored 129 papers that have together received 8.2k indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (52 papers), Toxin Mechanisms and Immunotoxins (39 papers), HER2/EGFR in Cancer Research (32 papers), Transgenic Plants and Applications (24 papers), CAR-T cell therapy research (14 papers), RNA and protein synthesis mechanisms (12 papers), Glycosylation and Glycoproteins Research (10 papers) and Lymphoma Diagnosis and Treatment (9 papers). The work is most often cited by research in Radiology, Nuclear Medicine and Imaging (3.9k citations), Oncology (4.0k citations), Biotechnology (797 citations), Immunology (1.8k citations) and Molecular Biology (3.4k citations). John M. Lambert has collaborated with scholars based in United States, United Kingdom and France. Frequent co-authors include Ravi Chari, Walter A. Blättler, Victor S. Goldmacher, Robert R. Traut, Peter D. Senter, Robert J. Lutz, Anna Berkenblit, Charles Morris, Alain Beck and Charles Dumontet. Their work appears in journals such as Biochemistry, Blood, Cancer Research, Journal of Biological Chemistry and Biochemical Journal.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.